Armin Ghobadi

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

Medicine, Hematology, Oncology +16

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

Medicine, Oncology, Pharmacology +12

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Medicine, Hematology, Oncology +8

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil, Michael D. Jain, Lei Feng et al. · Journal of Clinical Oncology · 2020 · 786 citations · Full text

Medicine, Hematology, Oncology +17

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

John S. Welch, Allegra A. Petti, Christopher A. Miller et al. · New England Journal of Medicine · 2016 · 784 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +17